“Serum Markers Predicting Early Non-Responsiveness to Infliximab in Rheumatoid Arthritis: Tumor Necrosis Factor (TNF)-Alpha, TNFRII, and Interleukin (IL)-17 As Potential Indicators”, IRAQI JMS, vol. 23, no. 1, Jun. 2025, doi: 10.22578/qchesh02.